tetano
Editor, Senior Moderator
Cell Rep Med
. 2022 Dec 15;100882.
doi: 10.1016/j.xcrm.2022.100882. Online ahead of print.
AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection
Anastasia A Aksyuk[SUP] 1 [/SUP], Himanshu Bansal[SUP] 2 [/SUP], Deidre Wilkins[SUP] 1 [/SUP], Ann Marie Stanley[SUP] 1 [/SUP], Stephanie Sproule[SUP] 2 [/SUP], Jill Maaske[SUP] 3 [/SUP], Satya Sanikommui[SUP] 2 [/SUP], William R Hartman[SUP] 4 [/SUP], Magdalena E Sobieszczyk[SUP] 5 [/SUP], Ann R Falsey[SUP] 6 [/SUP], Elizabeth J Kelly[SUP] 7 [/SUP]
Affiliations
Abstract
The nasal mucosa is an important initial site of host defense against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, intramuscularly administered vaccines typically do not achieve high antibody titers in the nasal mucosa. We measure anti-SARS-CoV-2 spike immunoglobulin G (IgG) and IgA in nasal epithelial lining fluid (NELF) following intramuscular vaccination of 3,058 participants from the immunogenicity substudy of a phase 3, double-blind, placebo-controlled study of AZD1222 vaccination (ClinicalTrials.gov: NCT04516746). IgG is detected in NELF collected 14 days following the first AZD1222 vaccination. IgG levels increase with a second vaccination and exceed pre-existing levels in baseline-SARS-CoV-2-seropositive participants. Nasal IgG responses are durable and display strong correlations with serum IgG, suggesting serum-to-NELF transudation. AZD1222 induces short-lived increases to pre-existing nasal IgA levels in baseline-seropositive vaccinees. Vaccinees display a robust recall IgG response upon breakthrough infection, with overall magnitudes unaffected by time between vaccination and illness. Mucosal responses correlate with reduced viral loads and shorter durations of viral shedding in saliva.
Keywords: AZD1222; COVID-19 vaccine; ChAdOx1 nCoV-19; SARS-CoV-2 spike antibodies; breakthrough infection; immunoassay; mucosal immune response; nasal antibody; nasal mucosal immunity; serology.
. 2022 Dec 15;100882.
doi: 10.1016/j.xcrm.2022.100882. Online ahead of print.
AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection
Anastasia A Aksyuk[SUP] 1 [/SUP], Himanshu Bansal[SUP] 2 [/SUP], Deidre Wilkins[SUP] 1 [/SUP], Ann Marie Stanley[SUP] 1 [/SUP], Stephanie Sproule[SUP] 2 [/SUP], Jill Maaske[SUP] 3 [/SUP], Satya Sanikommui[SUP] 2 [/SUP], William R Hartman[SUP] 4 [/SUP], Magdalena E Sobieszczyk[SUP] 5 [/SUP], Ann R Falsey[SUP] 6 [/SUP], Elizabeth J Kelly[SUP] 7 [/SUP]
Affiliations
- PMID: 36610390
- PMCID: PMC9750884
- DOI: 10.1016/j.xcrm.2022.100882
Abstract
The nasal mucosa is an important initial site of host defense against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, intramuscularly administered vaccines typically do not achieve high antibody titers in the nasal mucosa. We measure anti-SARS-CoV-2 spike immunoglobulin G (IgG) and IgA in nasal epithelial lining fluid (NELF) following intramuscular vaccination of 3,058 participants from the immunogenicity substudy of a phase 3, double-blind, placebo-controlled study of AZD1222 vaccination (ClinicalTrials.gov: NCT04516746). IgG is detected in NELF collected 14 days following the first AZD1222 vaccination. IgG levels increase with a second vaccination and exceed pre-existing levels in baseline-SARS-CoV-2-seropositive participants. Nasal IgG responses are durable and display strong correlations with serum IgG, suggesting serum-to-NELF transudation. AZD1222 induces short-lived increases to pre-existing nasal IgA levels in baseline-seropositive vaccinees. Vaccinees display a robust recall IgG response upon breakthrough infection, with overall magnitudes unaffected by time between vaccination and illness. Mucosal responses correlate with reduced viral loads and shorter durations of viral shedding in saliva.
Keywords: AZD1222; COVID-19 vaccine; ChAdOx1 nCoV-19; SARS-CoV-2 spike antibodies; breakthrough infection; immunoassay; mucosal immune response; nasal antibody; nasal mucosal immunity; serology.